Cronos revenue rises, costs jump 280% in second quarter
Cronos CEO warns losses will widen
Cronos Group posted a bigger-than-expected $17.8M adjusted loss in its second quarter, as costs ballooned. The company says higher processing costs and marketing expenses were partly to blame. On the conference call, CEO Mike Gorenstein also told investors to expect its adjusted EBITDA losses to widen in the second half of the year. Shares began the trading day higher but made their way into negative territory throughout the session.
Canopy's medical division strikes service agreement
Spectrum Therapeutics, Canopy's medical division, will now be Medical Pharmacies Group's preferred medical cannabis supplier and educator after striking a five-year service agreement. Medical Pharmacies is the largest specialty pharmacy in Canada and focuses on seniors in long-term care and retirement homes. Spectrum says its colour-coded products are especially appealing to seniors, who still face barriers when it comes to access and knowledge of medical cannabis.
Pot industry getting a pass on corporate governance
York University professor and governance expert Richard Leblanc says the entire pot industry has been getting a pass on corporate governance. In a BNN Bloomberg interview, Leblanc flagged a number of flaws in CannTrust’s boardroom practices including a lack of independence among its executive ranks and no formal whistleblowing procedure. He is calling on regulators to crack down on governance issues in the sector because shareholders are ultimately paying the price.
-- The average amount customers spent at Planet 13’s Las Vegas cannabis store in July
Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.